Patients taking Novo Nordisk's obesity drug Wegovy maintained an average of 10% weight loss for up to four years, according to a new analysis from the longest clinical trial to date on the treatment.
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
Investors interested in the pharmaceutical industry are currently excited about the anti-obesity market. Weight-loss ...
Several promising drugs in phase 2 testing and beyond seek to offer patients a more convenient alternative to already popular ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
While Novo Nordisk charges $1,349 a month for Wegovy in the U.S., the drug costs just $140 a month in Germany and $92 a month in the U.K. Novo Nordisk has blamed middlemen in the U.S. healthcare ...
As chronic kidney disease rises nationwide, a new study partially conducted in Orlando suggests weight loss drugs like ...
Structure Therapeutics’ GLP-1 receptor agonist GSBR-1290 achieved mean weight loss of 6.2% in overweight or obese patients.
Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...